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Abstract 
Aims: Clean intermittent catheterization (CIC) is recommended after spinal cord injury (SCI) because it has the least complications, 
however, CIC has a high discontinuation rate. We hypothesized that bladder botulinum toxin injection or augmentation cystoplasty 
may improve satisfaction with CIC. 
Methods: The NBRG registry is a multicenter, prospective, observational study asking SCI participants about neurogenic bladder 
(NGB) related quality of life (QoL). In this study, participants performing CIC as primary bladder management were categorized into 
3 groups: 1) CIC alone (CIC), 2) CIC with botulinum toxin (CIC-BTX), and 3) CIC with augmentation cystoplasty (CIC-AUG). 
Outcomes included primary: Neurogenic Bladder Symptom Score (NBSS) and SCI-QoL Bladder Management Difficulties, and 
secondary: NBSS subdomains (Incontinence, Storage & Voiding, Consequences) and the NBSS final question (satisfaction with 
urinary function). Multivariable regression, controlling for multiple factors was used to establish differences between the 3 groups. 
Results: 879 participants performed CIC as primary bladder management and had the following characteristics: mean age 43.4(± 
12.9) and years from injury 13.7(±10.7), tetraplegia in 284(32%), and 543(62%) were men. Bladder management was CIC in 
593(67%), CIC-BTX in 161(19%), and CIC-AUG in 125(15%). Primary outcomes: CIC-AUG had associated improved total NBSS 
versus CIC(-3.2(-5.2~-1.2),p=0.001 and CIC-BTX(-3.9(-6.3~-1.6),p=0.001), CIC-AUG also had better SCI-QoL Difficulties scores 
versus CIC(-4(-5.48~-2.53,p<0.001) and CIC-BTX(-4.4(-6.15~-2.65,p<0.001). Secondary outcomes: CIC-AUG had associated 
improved Incontinence and Satisfaction scores versus CIC and CIC-BTX. 
Conclusions: Compared to patients performing CIC with or without botulinum toxin treatment, those with augmentation cystoplasty 
had associated better urinary function and satisfaction with their urinary symptoms. 
 
Introduction  
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After spinal cord injury (SCI), most individuals are dependent upon some type of assisted bladder emptying. Commonly this involves 
urinary catheters. Physicians generally recommend clean intermittent catheterization (CIC), where a catheter is passed via the urethra 
or an abdominal stoma at regular intervals to drain the bladder. CIC is associated with a lower complication rate compared to 
indwelling catheters (IDC). For instance, SCI patients using IDCs have adverse bladder findings during urodynamic exams[1] and 
higher rates of upper tract abnormalities, proteinuria, and renal insufficiency.[2] In another study of thousands of patients enrolled 
nationally in the Model SCI system, patients with IDC had higher rates of urinary tract infection, urosepsis, hospitalizations, and 
sacral decubitus ulcers.[3] 
 Despite the lower complications associated with CIC, evidence suggests that most patients performing CIC at discharge from 
rehabilitation transition their bladder management to other methods, such as IDC.[3] Since very little that is known about quality of 
life (QoL) related to bladder management, the reasons for this transition are not clear. No doubt, many of the reasons for switching 
management have roots in QoL issues and indeed in one small study of CIC discontinuation, inconvenience and dislike were identified 
as important patient motivations for transition away from CIC.[4] 
Botulinum toxin was approved by the US Food and Drug Agency in 2011 for use in neurogenic bladder (NGB). In NGB 
patients, botulinum toxin can profoundly improve urinary continence and the ability to store urine at low pressures.[5] Augmentation 
cystoplasty (also called enterocystoplasty) is a surgery where the bladder is widely opened and a patch of bowel is sewn onto the 
bladder. The surgery expands the bladder’s volume and also decreases pressures and spasticity.[6] Both treatments have been 
demonstrated to have a profound impact on improving bladder function and lessening incontinence. Improved bladder function may 
Au
tho
r M
an
us
cri
pt
decrease inconvenience, encouraging patients to continue CIC rather than transitioning to less ideal bladder managements. Prior 
studies, which compared QoL between patients performing CIC and those patients who perform CIC and use botulinum toxin or have 
undergone augmentation cystoplasty were limited by small sample sizes and were underpowered to compare between the three 
treatments.[7, 8] 
In SCI patients who manage their bladder with CIC, we hypothesized that botulinum toxin injection or augmentation 
cystoplasty would be associated with improvements in patient-reported bladder function and QoL compared to those patients 
performing CIC alone. 
  
Materials and Methods: 
Study design: 
This study was a multicenter, prospective, observational study, which measures NGB-related quality of life after SCI. Participants 
were recruited throughout the United States and Canada. The study protocol, which details recruitment methods, duration, and aims 
has been previously published.[9] Eligibility included: age ≥18 years, English-speaking, acquired and non-progressive SCI (e.g., 
traumatic, spinal cord bleed / abscess / stroke, spinal cord tumor without active malignancy, transverse myelitis without progression to 
multiple sclerosis, and iatrogenic, such as laminectomy complication). Exclusion criteria were congenital causes of spinal cord 
problems, such as myelomeningocele or cerebral palsy, and progressive disorders such as multiple sclerosis. 
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Participants were asked about their bladder management during their enrollment interview. When participants used multiple bladder 
managements, such as a patient using a Foley catheter overnight but CIC during the day, they were asked what they considered as 
their main or primary method of management. For this study, all participants used CIC as their primary bladder management. The 
participants were grouped into (1) those using CIC alone (CIC), (2) those that were actively using botulinum toxin (CIC-BTX), and 
(3) those that had an augmentation cystoplasty (CIC-AUG). 
Botulinum toxin use was determined by asking “Are you using botulinum toxin injections (Botox) for your bladder?” If the 
answer was ‘yes’ than patients were grouped into CIC-BTX. We did not determine the timing the last injection relative to enrollment 
in the study. 
All participants had enterocystoplasty in the CIC-AUG group with or without creation of a catheterizable channel. Multiple 
bowel segments and techniques were used for augmentation cystoplasty and not all participants knew the type of augmentation that 
they had received. Participants with creation of a catheterizable channel without augmentation or a continent urinary pouch (i.e. 
Indiana Pouch involving complete bypass or removal of the bladder) were excluded from the study. 
 
Primary outcomes: 
The primary outcomes were (1) the Neurogenic Bladder Symptom Score (NBSS), and (2) the Spinal Cord Injury Quality of Life 
Measurement System (SCI-QoL) Bladder Management Difficulties (SCI-QoL Difficulties) item bank. The NBSS has been validated 
Au
tho
r M
an
us
cri
pt
in SCI and evaluates bladder function, as well as satisfaction with urinary function.[10, 11] The overall NBSS has a range of 0-74 with 
lower scores indicating better function. 
The spinal cord injury quality of life measurement system consists of many different item banks, validated specifically in SCI 
individuals, assessing all aspects of health and psychosocial impact of SCI.[12] We used the (SCI-QoL Difficulties) item bank, which 
assesses ability to carry out a bladder program, concerns about incontinence, and impact on daily life.[13] SCI-QoL questionnaires 
rely on item response theory and computer adaptive testing, which allows the questionnaire to adapt to a participant’s answer. SCI-
QoL item banks are calibrated to have a mean of 50 and a range of 0-100. Less bladder difficulties are indicated by a lower score. 
 
Secondary outcomes: 
The secondary outcomes included the three sub-dom ins of the NBSS: (1) Incontinence (range 0-29), (2) Storage & Voiding (range 0-
22), (3) Consequences (range 0-23), and a final QoL question asking about satisfaction with urinary function (Satisfaction) (range 0-
4).[10] 
 
Covariates: 
The factors we adjusted for when comparing QoL measures between the three management groups included: Demographics: (1) age 
(decades from injury), (2) gender, (3) obesity (body mass index>30 kg/m2), Injury characteristics: (4) level (tetraplegia / paraplegia 
including cauda equina), (5) time since injury in decades, (6) complete / incomplete injury - American Spinal Injury Association 
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Impairment Scale [ASI] ‘A’ or if unknown participants were asked if they had a complete or incomplete injury, (7) assisted 
catheterization – complete reliance upon others for catheterization, and SCI complications: (8) chronic pain (asked - do you 
experience chronic pain?), (9) number of UTIs in the last year (categorical - 0, 1-3, ≥4) – UTIs were self-defined by the patient, (10) 
hospitalization for UTI in last year, and (11) severe bowel dysfunction (Neurogenic Bowel Dysfunction Score > 14). The Neurogenic 
Bowel Dysfunction Score is a validated questionnaire about bowel function in neurogenic patients.[14] 
 
Statistical analysis: 
Baseline patient characteristics were summarized and compared across the 3 groups: (1) CIC (reference), (2) CIC-BTX, and (3) CIC-
AUG. In addition CIC-AUG was compared to CIC-BTX (reference). Continuous variables were compared using analysis of variance 
(ANOVA) or Kruskal-Wallis tests and categorical variables were compared using chi-squared tests. QoL outcome measures were 
compared across CIC management groups using univariate and multivariate linear regression models, where the multivariate models 
controlled for the factors described above in the “Covariates” section. For the CIC group (reference) we reported the predicted 
marginal mean of each QoL outcome with its 95% confidence interval (CI). For other management types and covariates in the model 
we report regression coefficients, which measured the magnitude of change in the outcome associated with that variable (negative 
change for the NBSS or the SCI-QoL indicated a better symptom burden or QoL), and their associated 95% CIs. Statistical analyses 
were conducted in R v. 3.4.1,[15] significance was assessed at the 0.05 level, and all tests were two-tailed. 
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Results: 
Study Participants: 
Over 18 months, 1479 eligible participants were enrolled and completed baseline questionnaires. From this group, 910 participants 
used CIC as their primary management and 879 met the inclusion criteria. Patients were excluded because of creation catheterizable 
channel alone without augmentation (n=24), or having a continent catheterizable pouch (n=7) (Figure 1). In the 125 patients in CIC-
AUG group, 79 (63%) had augmentation cystoplasty alone and 46 (37%) had augmentation cystoplasty combined with creation of a 
catheterizable channel. The mean time since augmentation cystoplasty to enrollment in the study was 10.1 (SD 8.1) years. 
 Table 1 summarizes the cohort’s characteristics. Overall, there were 543 (62%) men and the mean age and years from injury 
were 43.4 (SD 12.9) and 13.7 (SD 10.6) years. Compared to the CIC-alone and CIC-BTX groups, the CIC-AUG group was 
significantly more likely include female and quadriplegic patients. Some other significant differences existed between the CIC groups 
including: age, years since injury, chronic pain, and severe bowel dysfunction. There were no differences in the rate of UTIs or 
hospitalization for UTI between groups. The unadjusted primary and secondary outcome measures are compared between groups in 
Table 2. 
 
Primary outcomes: 
The CIC-AUG group had an associated better Global bladder function (total NBSS), compared to CIC and CIC-BTX (Table 3). 
Multiple variables were associated with improvement in the total NBSS, including: older age, male sex, tetraplegia, and increased 
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years since injury. A worse score was significantly associated with obesity, chronic pain, UTIs (both 1-3 and ≥ 4 per year), and severe 
bowel dysfunction. 
 There was also a better associated SCI-QoL Difficulties score in the CIC-AUG group compared to both CIC and CIC-BTX 
(Table 3). Similar to the NBSS, better scores were associated with: older age, male sex, tetraplegia, and increased years since injury; 
while obesity, UTIs (both 1-3, and ≥4 per year), and severe bowel dysfunction were all associated with worsened scores. There were 
no differences in either of the primary outcomes between CIC-BTX and CIC. 
 
Secondary outcomes: 
In the NBSS subdomains, CIC-AUG had associated better scores in the Incontinence subdomain and with Satisfaction compared to 
CIC and CIC-BTX (Table 4). The other subdomains, Storage & Voiding and Consequences, showed no differences between CIC-
AUG and CIC or CIC-BTX. There were no differences between CIC-BTX and CIC in any of the subdomains. 
 
Discussion: 
The best overall bladder function and satisfaction was associated with participants who had undergone augmentation cystoplasty 
compared to those performing CIC or those performing CIC and having current treatment with botulinum toxin. The improvements in 
bladder function were evidenced in global function (total NBSS), improved continence, and satisfaction with urinary system. In 
addition, SCI patients with augmentation cystoplasty had less bladder management difficulties, although the magnitude of change was 
Au
tho
r M
an
us
cri
pt
smaller than changes in the NBSS, when compared to the marginal means in the multivariable model. There were no differences in 
any patient-reported outcomes between patients treated with botulinum toxin and those doing CIC alone. 
 The research published about QoL with different bladder management methods among SCI patients is heterogeneous and 
mostly relies upon general QoL measures rather and bladder specific patient-reported outcome measures. There are very few studies 
evaluating the influence of surgery on QoL. One of the few studies looking at the influence of surgery, by Adriaansen et al, used the 
short form of the Qualiveen NGB QoL questionnaire to evaluate differences in bladder management in SCI patients.[7] This 
questionnaire is similar to the SCI-QoL Difficulties used in our study, and assess feelings and limitations related to NGB.[16] The 
authors found on univariate analysis that patients having surgery, either continent (n=8) or incontinent urinary diversion (n=8), had 
improved QoL compared to patients performing CIC. The study results were limited by the small number of patients. 
 Another study, by Anquetil et al, evaluated differences in QoL between patients with a history of augmentation cystoplasty 
and those receiving botulinum toxin using the full Qualiveen questionnaire to compare groups.[8] Patients with augmentation (n=16) 
had improved overall QoL, as well as improvement in the subdomain of Limitations and Constraints compared to those using 
botulinum toxin (n=14). These were substantial differences and represented improved scores ranging between 29-56%. In comparison, 
we found the improvement in augmentation patients in the SCI-QoL Difficulties was only an approximately a 7% improvement (-4.4 
on a scale of 0-100, with marginal means of 58.3 [CIC reference]). However, in the study by Anquetil et al, 13% of patients in the 
botulinum toxin group did not perform CIC and relied on condom catheters, IDCs or leakage into diapers. Poor QoL associated with 
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these managements within the botulinum toxin group might have created a much larger gap in QoL between treatment groups 
compared to our study where all patients were performing CIC. Again this study was limited by small numbers in comparison groups.  
 Among the potential confounding variables, we included dependence upon others for catheterization. Independence is valued 
by SCI individuals[12] and so there is an intuitive link between worse QoL and dependence upon others. One study by Akkoc et al, 
noted that QoL, measured by the King’s Health Questionnaire, was worse among CIC patients that are reliant on others for 
catheterization.[17] On our multivariate analysis, we found no association between assisted catheterization and worse bladder function 
or QoL. Our patients on average were 14 years from injury and SCI patients probably developed mature resources for assistance over-
time. One can infer from our data, that if a patient has reliable help and desires to continue or to start CIC, reliance upon others for 
catheterization should not be a barrier to treatments to optimize CIC, such as botulinum toxin injection or even augmentation 
cystoplasty. 
 Botulinum toxin has been associated with dramatic improvements in QoL in SCI patients. The two landmark randomized 
trials leading to approval of botulinum toxin in Europe and the United States assessed QoL of life and bladder function with the 
Incontinence Quality of Life score (IQOL).[5, 18] This is a bladder specific questionnaire focused upon incontinence and has been 
validated in NGB.[19] These studies showed that after botulinum toxin injection IQOL scores were dramatically improved, as well as 
urodynamic parameters and incontinence episodes. In these studies, there was significantly better QoL in participants that received 
botulinum toxin compared to those that did CIC and received placebo. In contrast, we did not find any differences between these 
groups; however, the studies are very different and patients entering the randomized controlled trials presumably were having bladder 
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difficulties and electing to enter a clinical trial to try to improve their bladder function. This is evidenced by the very high rate of 
incontinence episodes at baseline in the study as well as the very low IQOL scores. In contrast, our study was a crossectional survey 
that presumably captures patients with a spectrum of bladder function including many patients doing very well with their current 
management. Despite the lack of differences, in our study, in bladder function or QoL in patients using botulinum toxin compared to 
patients doing CIC with standard NGB management, the efficacy of botulinum toxin is evidenced by the fact that a full 21% of 
patients in our study that not had augmentation cystoplasty were actively using botulinum toxin. 
 Our data is cross-sectional and unlike the randomized trials of botulinum toxin efficacy, we are not able assess pre and post 
interventions. One of the best ways to use our data is in shared decision making with SCI patients who are seeking help for urinary 
problems and want to continue to perform CIC. These patients, if they are appropriately chosen, can be counseled that their bladder 
related function after botulinum toxin injection should approximate on average patients that are doing well with CIC and standard 
NGB management. Those patients that are not good candidates for botulinum toxin or if the drug loses its positive effects, and elect to 
undergo augmentation cystoplasty can expect to have comparable or even better bladder function and QoL than individuals that are 
performing CIC with or without the use of botulinum toxin. It needs to be acknowledged that NGB management is not static in time 
and individuals may do well with standard management for a variable time period and then worsen and progress to needing botulinum 
toxin and in some cases augmentation cystoplasty. Our data does not indicate the SCI individuals should have augmentation 
cystoplasty, but rather indicates that when patient progress to the need for augmentation cystoplasty they will have excellent bladder 
function and QoL associated with the surgery. 
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One limitation of this study is that the nature of the survey data may have introduced inclusion bias into those responding and 
enrolling into the study. The study obviously involved bladder management problems and people with SCI and urinary problems may 
have enrolled in the study at higher rates in hopes of learning more about NGB. In addition, those participants with a history of 
augmentation cystoplasty may have confirmation bias, which might influence their bladder related QoL positively. Another limitation 
is that we lacked information about the timing of the last injection of botulinum toxin. Participants in the CIC-BTX group stated they 
were actively using botulinum toxin, however, it was not possible for us to determine whether they were in a therapeutic window of 
time to be considered actively treated with the drug. We also did not have any objective data on the function of the patients' bladders, 
such as bladder journals or urodynamic studies. This type of data could not be practically collected on such a diverse population of 
participants from across the United States and Canada. An additional limitation was the exclusion of patients that had creation of a 
catheterizable channel alone without augmentation cystoplasty. We were unsure if these patients would have QoL more like 
augmented patients or those never having had augmentation. After creation of a catheterizable channel nothing is fundamentally done 
to the bladder spasticity or pressures; however, patients may have had substantial improvements in QoL associated with facilitating 
their ability to catheterize. There were too few patients undergoing creation of a catheterizable channel to perform a sub-analysis of 
QoL. 
 
Conclusions: 
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Among patients performing CIC, those who underwent augmentation cystoplasty had better associated bladder function, fewer bladder 
management difficulties, and higher satisfaction than those performing CIC with or without botulinum toxin use. Our study provides 
reassuring data that as surgeons we are providing our patients with therapy that they rate as having positive impact upon bladder 
related function and QoL. 
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Table 1: Characteristics of the 879 participants who performed CIC. 
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CIC (clean intermittent catheterization), CIC-BTX (CIC with current use of botulinum toxin), CIC-AUG (CIC with prior augmentation cystoplasty with or 
without catheterizable channel), BMI (body mass index), complete injury - American Spinal Injury Association Impairment Scale [ASI] ‘A’ or if unknown 
participants asked if they had a complete or incomplete injury, assisted catheterization – complete reliance on others for catheterization, chronic pain – 
participants asked “do you experience chronic pain?”, UTI (urinary tract infection), number of UTIs and hospitalization in last year, severe bowel dysfunction – 
Neurogenic Bowel Dysfunction Score ≥ 14. Missing data: Obese (n=11), Assisted Catheterization (n =1), Chronic Pain (n=2), Severe Bowel Dysfunction (n 
=46). 
Table 2: Summary of primary and secondary outcomes and comparison between three groups. 
Variable All patients  CIC CIC-BTX CIC-AUG P-value 
Number of Participants 879  593 (67%) 161 (18%) 125 (14%)  
Surgery       
Augmentation      79 (63%)  
Augmentation + catheterizable channel     46 (27%)       
Demographics       
Age - Mean (SD) 43.4 (12.9)  44.3 (12.9) 41.4 (13.4) 41.8 (11.9) 0.014 
 - Median (IQR) 43 (33, 53.2)  44.3 (34.3, 53.6) 39.5 (30, 51.9) 40.7 (31.3, 51.8) - 
 - Range (18, 86)  (18, 78.5) (18.4, 86) (19, 67.9) - 
Sex-Male 543 (62%)  408 (69%) 97 (60%) 38 (30%) <0.001 
Obese (BMI > 30 kg/m2) 194 (22%)  135 (23%) 28 (18%) 31 (25%) 0.22 
Injury Characteristics       
Level Tetraplegia 284 (32%)  172 (29%) 57 (35%) 55 (44%) 0.003 
 Paraplegia 595 (68%)  421(71%) 104 (65%) 70 (56%) - 
Years Since Injury - Mean (SD) 13.7 (10.6)  13.9 (11) 10.6 (8.5) 16.5 (10.4) <0.001 
 - Median (IQR) 10.4 (5.1, 20.8)  10.7 (4.9, 21.8) 8.1 (4.5, 13.8) 15.1 (8.2, 23.2) - 
 - Range (0, 50.4)  (0, 48.3) (0.7, 36.8) (1, 50.4) - 
Complete Injury 375 (43%)  236 (40%) 78 (49%) 61 (49%) 0.049 
Assisted Catheterization 94 (11%)  54 (9%) 28 (17%) 12 (10%) 0.010 
SCI Complications       
Chronic Pain 596 (68%)  395 (67%) 104 (65%) 97 (78%) 0.041 
Number of UTIs       
0 209 (24%)  141 (24%) 32 (20%) 36 (29%) 0.52 
1-3 428 (49%)  291 (49%) 81 (50%) 56 (45%) - 
≥ 4 242 (28%)  161 (27%) 48 (30%) 33 (26%) - 
Hospitalization for UTI 89 (10%)  59 (10%) 19 (12%) 11 (9%) 0.68 
Severe Bowel Dysfunction 333 (40%)  204 (36%) 68 (45%) 61 (52%) 0.002 
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CIC (clean intermittent catheterization), CIC-BTX (CIC with current use of botulinum toxin), CIC-AUG (CIC with prior augmentation cystoplasty with or 
without catheterizable channel), NBSS (Neurogenic Bladder Symptom Score), SCI-QoL (Spinal Cord Injury Quality of Life Measurement System), SCI-QoL 
Difficulties (SCI-QoL Bladder Management Difficulties) 
Table 3: Primary Outcomes: Multivariate linear regression comparing the NBSS and SCI-QoL Difficulties between patients performing CIC-
BTX vs. CIC, CIC-AUG vs. CIC, and CIC-AUG vs. CIC-BTX adjusting for patient characteristics. Unless otherwise specified, results include 
the regression coefficient, 95% Cis, and p-values, indicating the change in the outcome associated with each predictor. 
  
Variables NBSS total P-value SCI-Qol Difficulties P-value 
Bladder Management     
CIC* 24.8(23.9~25.7)  58.3(57.6~58.9) - 
CIC-BTX 0.7(-1~2.4)  0.44 0.4(-0.87~1.67)  0.54 
CIC-AUG -3.2(-5.2~-1.2)  0.001 -4(-5.48~-2.53) <0.001 
 All patients  CIC CIC-BTX CIC-AUG P-value 
Primary Outcomes       
NBSS - Mean (SD) 25 (10.1)  24.9 (10.2) 26.6 (9.6) 23.3 (9.7)  0.020 
 - Median (IQR) 24 (17.5, 32)  24.0 (17.0, 32.0) 27.0 (20.0, 33.0) 24.0 (15.0, 30.0)  
 - Range (1, 63)  (3.0, 63.0) (1.0, 55.0) (3.0, 48.0)  
SCI-QoL Difficulties - Mean (SD) 58.3 (7.4)  58.6 (7.3) 59.5 (7.1) 55.3 (7.3) <0.001 
 - Median (IQR) 58.8 (54.4, 62.9)  59.9 (54.4, 62.9) 59.9 (56.6, 64.1) 56.6 (49.6, 60.1)  
 - Range (37.6, 82.1)  (37.6, 81.5) (37.6, 82.1) (37.6, 74.3)  
Secondary Outcomes       
NBSS Incontinence - Mean (SD) 10.4 (6.8)  10.5 (6.8) 11.6 (6.6) 8.8 (6.6)  0.002 
 - Median (IQR) 11 (6, 15)  11.0 (6.0, 15.0) 12.0 (8.0, 16.0) 9.0 (2.0, 13.0)  
 - Range (0, 28)  (0.0, 28.0) (0.0, 25.0) (0.0, 25.0)  
NBSS Storage & Voiding - Mean (SD) 7.8 (3.3)  7.8 (3.4) 7.9 (3.3) 7.7 (3.1)  0.90 
 - Median (IQR) 8 (5, 10)  8.0 (5.0, 10.0) 8.0 (6.0, 10.0) 7.0 (6.0, 10.0)  
 - Range (0, 19)  (0.0, 19.0) (1.0, 17.0) (2.0, 18.0)  
NBSS Consequences - Mean (SD) 6.8 (2.9)  6.6 (3.0) 7.2 (2.6) 6.8 (3.1)  0.12 
 - Median (IQR) 7 (5, 8.5)  6.0 (5.0, 8.0) 7.0 (6.0, 8.0) 7.0 (5.0, 9.0)  
 - Range (0, 20)  (0.0, 19.0) (0.0, 20.0) (0.0, 13.0)  
NBSS Satisfaction - Mean (SD) 2.1 (1.2)  2.2 (1.2) 2.2 (1.1) 1.4 (1.1) <0.001 
 - Median (IQR) 2 (1, 3)  2.0 (1.0, 3.0) 2.0 (1.0, 3.0) 1.0 (1.0, 2.0)  
 - Range (0, 4)  (0.0, 4.0) (0.0, 4.0) (0.0, 4.0)  
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Variables NBSS total P-value SCI-Qol Difficulties P-value 
CIC-AUG vs. CIC-BTX** -3.9(-6.3~-1.6)  0.001 -4.4(-6.15~-2.65) <0.001 
Demographics     
Age -0.7(-1.3~-0.1)  0.014 -0.64(-1.05~-0.22)  0.003 
Sex-Male -3.7(-5.1~-2.3) <0.001 -1.8(-2.85~-0.75) <0.001 
Obese (BMI > 30 kg/m2) 1.8(0.2~3.4)  0.026 1.23(0.06~2.4)  0.039 
Injury Characteristics     
Level Tetraplegia -2.5(-4.1~-0.9)  0.002 -2.27(-3.45~-1.09) <0.001 
Years Since Injury -0.9(-1.5~-0.2)  0.013 -0.9(-1.41~-0.4) <0.001 
Complete Injury -0.3(-1.6~1.1)  0.69 -0.38(-1.39~0.64)  0.47 
Assisted Catheterization 1.7(-0.6~4)  0.15 0.02(-1.7~1.74)  0.98 
SCI Complications     
Chronic Pain 1.7(0.3~3.1)  0.014 0.87(-0.16~1.9)  0.10 
Number of UTIs     
1-3 1.9(0.3~3.5)  0.020 1.26(0.07~2.45)  0.038 
≥ 4 5.7(3.8~7.5) <0.001 2.96(1.57~4.34) <0.001 
Hospitalization for UTI 1.7(-0.5~3.9)  0.13 -1.12(-2.75~0.52)  0.18 
Severe Bowel Dysfunction 1.7(0.3~3)  0.013 1.18(0.2~2.15)  0.018 
* Predicted marginal means for CIC were reported with 95% confidence intervals (CIs), reflecting an average of model predictions when management type is CIC, at all 
combinations of levels of other categorical predictors weighted by the frequencies of these combinations in the data set with continuous variables set to their sample means. 
**Estimated from the same model but switching the reference level to CIC-BTX. 
NBSS (Neurogenic Bladder Symptom Score), SCI-QoL (Spinal Cord Injury Quality of Life Measurement System), SCI-QoL Difficulties (SCI-QoL Bladder Management 
Difficulties), CIC (clean intermittent catheterization), CIC-BTX (CIC with current use of botulinum toxin), CIC-AUG (CIC with prior augmentation cystoplasty with or 
without catheterizable channel), age (in decades), BMI (body mass index), Years since injury (decades from injury), complete injury - American Spinal Injury Association 
Impairment Scale [ASI] ‘A’ or if unknown participants asked if they had a complete or incomplete injury), assisted catheterization – complete reliance on others for 
catheterization, chronic pain – participants asked “do you experience chronic pain?”, UTI (urinary tract infection), number of UTIs and hospitalization in last year, severe 
bowel dysfunction – Neurogenic Bowel Dysfunction Score ≥ 14. Multivariate linear regressions were used to compare NBSS score and each of its subdomain scores 
(Incontinence, Storage & Voiding, and Consequences), as well as Satisfaction across CIC types adjusting for covariates. For CIC (reference level of management type), 
predicted marginal means were reported with 95% confidence intervals (CIs), reflecting an average of model predictions when management type is CIC, at all combinations 
of levels of other categorical predictors weighted by the frequencies of these combinations in the data set with continuous variables set to their sample means. For other 
predictors in the model, regression coefficient, 95% CIs and p-values were reported, indicating change in the outcome associated with the predictor. 
Table 4: Secondary outcomes: Multivariate linear regression comparing NBSS subdomains, and the final question about satisfaction between 
patients performing CIC-BTX vs. CIC, CIC-AUG vs. CIC, and CIC-AUG vs. CIC-BTX adjusting for patient characteristics. Unless otherwise 
specified, results include the regression coefficient, 95% Cis, and p-values, indicating the change in the outcome associated with each predictor. 
 
 NBSS Subdomains        
Variables Incontinence P-value Storage & Voiding P-value Consequences P-value Satisfaction P-value 
Bladder Management         
CIC* 10.3(9.7~10.9)  7.8(7.5~8.1)  6.7(6.4~6.9)  2.2(2.1~2.3)  
CIC-BTX 0.39(-0.77~1.54)  0.51 0.01(-0.6~0.62)  0.97 0.3(-0.2~0.7)  0.23 -0.16(-0.36~0.04)  0.12 
CIC-AUG -2.75(-4.09~-1.42) <0.001 -0.41(-1.11~0.3)  0.26 -0.1(-0.6~0.5)  0.81 -0.81(-1.05~-0.58) <0.001 
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 NBSS Subdomains        
Variables Incontinence P-value Storage & Voiding P-value Consequences P-value Satisfaction P-value 
CIC-AUG vs. CIC-BTX** -3.14(-4.72~-1.56) <0.001 -0.42(-1.25~0.41)  0.32 -0.3(-1~0.3)  0.29 -0.65(-0.93~-0.37) <0.001 
Demographics         
Age -0.3(-0.67~0.08)  0.12 -0.21(-0.4~-0.01)  0.038 -0.2(-0.3~0)  0.013 0(-0.07~0.06)  0.95 
Sex-Male -2.85(-3.8~-1.91) <0.001 -0.81(-1.31~-0.31)  0.002 -0.1(-0.4~0.3)  0.78 -0.25(-0.42~-0.09)  0.003 
Obese (BMI > 30 kg/m2) 1.34(0.28~2.4)  0.013 0.3(-0.26~0.86)  0.29 0.1(-0.3~0.6)  0.49 -0.02(-0.2~0.17)  0.85 
Injury Characteristics         
Level Tetraplegia -2.99(-4.06~-1.92) <0.001 0.27(-0.3~0.83)  0.35 0.3(-0.2~0.7)  0.25 -0.13(-0.32~0.06)  0.18 
Years Since Injury -0.81(-1.26~-0.35) <0.001 -0.21(-0.4~-0.01)  0.038 00.1(-0.1~0.2)  0.49 -0.3(-0.38~-0.22) <0.001 
Complete Injury 0.73(-0.18~1.65)  0.12 -1.01(-1.49~-0.53) <0.001 0(-0.4~0.4)  0.98 -0.14(-0.3~0.02)  0.09 
Assisted Catheterization 1.05(-0.51~2.6)  0.19 -0.16(-0.98~0.66)  0.70 0.8(0.2~1.4)  0.013 0.08(-0.19~0.36)  0.55 
SCI Complications         
Chronic Pain 0.72(-0.21~1.66)  0.13 0.59(0.1~1.08)  0.019 0.4(0~0.8)  0.028 0.14(-0.03~0.3)  0.10 
Number of UTIs         
1-3 -0.02(-1.09~1.06)  0.97 0.26(-0.31~0.83)  0.37 1.7(1.2~2.1) <0.001 0.22(0.03~0.41)  0.023 
≥ 4 1.54(0.29~2.79)  0.016 0.58(-0.08~1.23)  0.09 3.5(3~4.1) <0.001 0.57(0.35~0.78) <0.001 
Hospitalization for UTI -0.11(-1.57~1.35)  0.92 0.82(0.04~1.59)  0.038 1(0.4~1.6)  0.001 -0.22(-0.48~0.04)  0.09 
Severe Bowel Dysfunction 0.86(-0.02~1.74)  0.06 0.37(-0.09~0.84)  0.12 0.4(0.1~0.8)  0.019 0.25(0.09~0.4)  0.002 
* Predicted marginal means for CIC were reported with 95% confidence intervals (CIs), reflecting an average of model predictions when management type is CIC, at all 
combinations of levels of other categorical predictors weighted by the frequencies of these combinations in the data set with continuous variables set to their sample means. 
**Estimated from the same model but switching the reference level to CIC-BTX. 
NBSS (Neurogenic Bladder Symptom Score), CIC (clean intermittent catheterization), CIC-BTX (CIC with current use of botulinum toxin), CIC-AUG (CIC with prior 
augmentation cystoplasty with or without catheterizable channel), age (in decades), BMI (body mass index), Years since injury (decades from injury), complete injury - 
American Spinal Injury Association Impairment Scale [ASI] ‘A’ or if unknown participants asked if they had a complete or incomplete injury), assisted catheterization – 
complete reliance on others for catheterization, chronic pain – participants asked “do you experience chronic pain?”, UTI (urinary tract infection), number of UTIs and 
hospitalization in last year, severe bowel dysfunction – Neurogenic Bowel Dysfunction Score ≥ 14. Multivariate linear regressions were used to compare NBSS score and 
each of its subdomain scores (Incontinence, Storage & Voiding, and Consequences), as well as Satisfaction across CIC types adjusting for covariates. For CIC (reference 
level of management type), predicted marginal means were reported with 95% confidence intervals (CIs), reflecting an average of model predictions when management type 
is CIC, at all combinations of levels of other categorical predictors weighted by the frequencies of these combinations in the data set with continuous variables set to their 
sample means. For other predictors in the model, regression coefficient, 95% CIs and p-values were reported, indicating change in the outcome associated with the predictor. 
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Figure 1 
